US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Abstract
No abstract available
Domains
Human health and pathology
Fichier principal
Manuscript_R2_clean.pdf (382.08 Ko)
Télécharger le fichier
Fig with arrows.pdf (80.26 Ko)
Télécharger le fichier
Origin | Files produced by the author(s) |
---|